http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
국내 에이즈환자에서 발견된 새로운 인간면역부전 바이러스 아형
김남중,이선희,박상원,최희정,김도마,최정윤,김진욱,김의석,Feng Gao,오명돈,최강원 대한감염학회 2001 감염 Vol.33 No.2
Backgroud : In the previous study, we determined subtypes of Human Immunodeficiency Virus type 1 (HIV-1) in Korean patients by partial sequence analysis. We showed that eighteen of the nineteen sequences of HIV-1 from Korean fell into subtype B and one fell into subtype A. At that study, HIV-1 identified as subtype A showed 40% diversity from reference sequences and presumed to be a variant of subtype A. The aim of present study is to determine the molecuar biological characteristics of HIV-1 previously identified as subtype A. Methods : Growth curve was determined. SI/NSI phenotype was determined using a cocultivation assay using MT-2 cells. A complete genome sequence was obtained by amplifying overlapping PCR fragments. Cowork was done to identify the subtype of HIV-1 previously identified as variant A from Korea (97-KRO04), Cyprus (94CY017), Democratic Republic of Congo (97CDKTB48, 97CDKFE4, 97CDKS10, 97-CDKP58). Phylogenetic analysis, distance analysis, diversity plot analysis, bootstrap anlysis were done to identify the subtype of these newly characterized strains. Results : We found that 97KR004 was SI pheno-type. Complete sequence of 97KR004 was determined (AF286239). Phylogenetic analysis showed that the four newly characterized strains (94CY017, 97CDKTB-48, 97CDKFE4, 97CDKS10) were closely related to subtype A. Subtype distance tool showed that these four strains fell to sub-subtype A2. Diversity plot an-alysis and bootstrap analysis were done to identify subtype of 97KR004. Nine subtype reference strains and 94CY017 strain were used as reference sequences. These analyses confirmed that 97KR004 represented sub-subtype A2/subtype D recombinant. Conclusion : We showed that 97KR004 fell into newly identified sub-subtype A2. (Korean J Infect Dis 33:71∼77, 2001)
이선희,김남중,김의석,방지환,김도마,오명돈,최강원 대한감염학회 2001 감염 Vol.33 No.1
Background : To evaluate the clinical efficacy, safety and tolerance of combination therapy of zidovudine, lamivudine and indinavir in HIV infected patients. Methods : We reviewed medical records of HIV infected patients who had received combination therapy of zidovudine, lamivudine and indinavir at the Seoul National University Hospital between May 1998 and March 1999. The clinical end point was the time to the development of the opportunistic infection or death. Changes in plasma HIV-1 RNA levels and CD4 cell counts before and after combination treatments were also evaluated. Results : Fifty-two patients were included in this study. Of these, 25 patients (48%) had continued the treatment more than 6 months, whereas 12 patients (23%) were lost to follow-up, and 15 patients (29%) had discontinued the treatment. The causes of discontinuation of the treatment were adverse drug effects in 67% (10/15), economic problem in 20% (3/15) and the development of drug resistance in 13% (2/15). Of the 25 patients who had been treated more than 6 months, 4 patients were excluded because they had not taken the necessary tests at the scheduled time points. Of the 21 evaluable patients, 3 patients (14%) developed opportunistic infections, but no patients died. In seventeen patients (81%), HIV RNA-1 titers decreased below the detectable level by 6 months of treatment. The mean decrease of HIV-1 RNA titer after 6 months of treatment was 2.65 log10 copies/mL. The mean increase of CD4 cell counts was 111 cells/mm3. Conclusion : Combination therapy of zidovudine, lamivudine and indinavir was effective in decrease of viral load and increase of CD4 cell counts. Half of the patients could not continue the combination therapy more than 6 months because of the adverse drug effects and/or economical problem. (Korean J Infect Dis 33:46∼51, 2001)